Table 3. Multivariate Cox proportional hazards regression of the training & independent validation series (stage 2 and 3 patients) using clinical factors and gene expression risk groups.
Training series (DFS)
|
Training series (DSS)
|
Validation series (DFS)
|
||||
---|---|---|---|---|---|---|
Covariate | P-value | Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) |
Age | 0.38 | 0.99 (0.96–1.01) | 0.38 | 1.01 (0.98–1.05) | 0.31 | 0.98 (0.93–1.02) |
Gender (M) | 0.59 | 0.81 (0.38–1.74) | 0.97 | 0.98 (0.40–2.42) | 0.22 | 0.49 (0.16–1.52) |
Grade | 0.96 | 1.02 (0.50–2.05) | 0.95 | 1.02 (0.43–2.43) | — | — |
Stage (3) | 0.07 | 2.04 (0.95–4.41) | 0.28 | 1.66 (0.65–4.22 | 0.0021 | 9.23 (2.26–37.70) |
Adjuvant chemotherapy | — | — | 0.22 | 0.43 (0.12–1.62) | ||
Adjuvant radiotherapy | — | — | 0.32 | 3.35 (0.31–36.095) | ||
Gene expression risk group (high risk) | 0.0018 | 4.22 (1.72–10.39) | 0.004 | 19.13 (2.59–141.54) | 0.061 | 3.042 (0.96–9.69) |
Abbreviations: CI=confidence interval; DFS=disease-free survival; DSS=disease-specific survival.